hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06272448, orgStudyIdInfo id: CERM2022-27 21042022, briefTitle: teleRehabilitation for pAtients With ParkInson's Disease at Any mOment, acronym: RAPIDO, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-15, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Università Politecnica delle Marche, class: OTHER, collaborators name: Universita di Verona, descriptionModule briefSummary: The goal of this clinical trial is to test the feasibility and safety of a telerehabilitation and telemonitoring approach in people with Parkinson's disease at any stage. The main questions it aims to answer are: will patients with Parkinson's disease comply with the recommended level of training at home using an ad hoc developed telerehabilitation platform? • Will this training be safe and impact the patient's well-being perception? Participants will be given a tablet and instructed to access an online platform to observe different motor tasks presented in as many video clips by experienced therapists.They will be requested to perform the motor tasks per a predetermined protocol over 3 months. Their compliance with the recommended training will be checked by physiotherapists every 15 days during phone calls, whereas their daily level of motor activity will be recorded by a smartwatch., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Before-after study with one follow-up at 3 months of treatment end, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Telerehabilitation, outcomesModule primaryOutcomes measure: Compliance with the telerehabilitation system, primaryOutcomes measure: Perceived usability of system, primaryOutcomes measure: Incidence of treatment-emergent adverse events, secondaryOutcomes measure: User satisfaction, secondaryOutcomes measure: Compliance with the monitoring system, secondaryOutcomes measure: Feasibility of telemonitoring approach, secondaryOutcomes measure: Motor symptom and disability progression, secondaryOutcomes measure: Non motor symptom progression, secondaryOutcomes measure: Patients' Quality of life, secondaryOutcomes measure: Caregiver's burden, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Neurorehabilitation Clinic, status: RECRUITING, city: Ancona, zip: 60126, country: Italy, contacts name: Elisa Andrenelli, Dr, role: CONTACT, phone: 0715965794, email: e.andrenelli@univpm.it, geoPoint lat: 43.5942, lon: 13.50337, locations facility: Università di Verona, status: RECRUITING, city: Verona, zip: 37100, country: Italy, contacts name: Marialuisa Gandolfi, Prof, role: CONTACT, phone: +39 045 812 4943, email: marialuisa.gandolfi@univr.it, geoPoint lat: 45.4299, lon: 10.98444, hasResults: False
protocolSection identificationModule nctId: NCT06272422, orgStudyIdInfo id: 2022/0472, secondaryIdInfos id: 2023-A00358-37, type: OTHER, domain: IDRCB - ANSM ID, briefTitle: Comparison of the Restoration of Hip Biomechanical Parameters by CT Measurement Between the 3 Surgical Techniques: RSA/Minihip/THA - Hip Replacement: 3D Planning, acronym: HIP3D, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University Hospital, Lille, class: OTHER, descriptionModule briefSummary: The study will analyze hip biomechanical parameters using EOS radiographic measurements pre- and post-operatively (3 months) and post-operatively (3 months) CT scans after total hip replacement (THR), neck-preserving THR of the Minihip type or hip resurfacing (HR). Clinical results will be assessed at 3 months and 1 year after surgery.To this end, two types of examination are carried out, both of which are used in current practice:* Pre-operatively: EOS radiography* Post-operatively: EOS radiograph and CT scanInclusion (m-3; m-1) :* Patient information at pre-operative visit* Non-opposition of patient, family member or legal guardian, if applicable* Questionnaires and clinical examination (standard management)* EOS during anesthetic consultationFollow-up visit (m+3):- Post-operative follow-up consultation EOS and CT scan (1 week prior to visit) + questionnaire and clinical examinationFollow-up visit (m+12):- Post-operative check-up, questionnaire and clinical examination, conditionsModule conditions: Coxarthrosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 165, type: ESTIMATED, armsInterventionsModule interventions name: hip arthroplasty, outcomesModule primaryOutcomes measure: Comparing the restoration of femoral hip offset between hip resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty., secondaryOutcomes measure: Compare the anatomical restoration of frontal and axial parameters between the 3 types of intervention (PTH, Minihip and RSA)., secondaryOutcomes measure: Compare clinical outcomes and patient satisfaction between the 3 procedures (PTH, Minihip and RSA)., secondaryOutcomes measure: Correlate restoration of hip femoral offset and patient functional outcome at 3 months., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272409, orgStudyIdInfo id: DEP114-III-0123, briefTitle: Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children., acronym: SIERRA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-02-15, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2027-04-15, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: EMS, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years., conditionsModule conditions: Allergic Rhinitis, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 318, type: ESTIMATED, armsInterventionsModule interventions name: DEP114, interventions name: Desloratadine 0.5 MG/ML, outcomesModule primaryOutcomes measure: To demonstrate the superiority of DEP114 in relation to desloratadine 0.5 mg/mL in relieving the nasal symptoms of moderate to severe persistent allergic rhinitis in children, five days after starting treatment., secondaryOutcomes measure: To evaluate the effectiveness of DEP114 in relieving nasal symptoms of moderate to severe persistent allergic rhinitis in children, throughout the treatment., secondaryOutcomes measure: Evaluate the efficacy of DEP114 to relieve nasal obstruction present in moderate to severe persistent allergic rhinitis in children through the treatment., secondaryOutcomes measure: Evaluate the efficacy of DEP114 to relieve coryza present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment., secondaryOutcomes measure: Evaluate the efficacy of DEP114 to relieve nasal itching present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment., secondaryOutcomes measure: Evaluate the efficacy of DEP114 to relieve sneezing present in persistent allergic rhinitis moderate to severe in children, three and five days after the start of treatment., secondaryOutcomes measure: Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the perception of the person responsible for the participant., secondaryOutcomes measure: Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the investigator's perception., eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 11 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06272383, orgStudyIdInfo id: HS26166 (B2023:092), briefTitle: Croup Dosing Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University of Manitoba, class: OTHER, descriptionModule briefSummary: Croup is a common childhood respiratory disease that often leads to frequent emergency department visits. It is a viral infection that causes cough, throat, and airway swelling, making breathing difficult. Dexamethasone is a medication that helps to reduce swelling, making breathing easier for children. A standard dose of 0.6mg/kg is used in children. However, a lower amount (due to side effects of steroids in children) has been suggested. We will examine whether 25% less than the standard dose is equally effective in treating croup. Investigators will conduct a clinical study with the support of patients with lived experience (which, in this case, are the parents of the children) to better care for children with croup. If proven, this study can improve the outcome in children with croup., conditionsModule conditions: Croup, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is an internal double-blinded vanguard randomized controlled trial (RCT), which will be conducted at the Winnipeg Children's Hospital (WCH). Computerized randomization will be performed by a statistician at the George and Fay Yee Centre for HealthCare Innovation to generate the randomization list. Investigators will perform a computerized randomization stratified by age. Investigators will do a block randomization with random blocks of undisclosed block sizes over the seasons to ensure temporal distribution of croup cases is captured. Investigators will randomly assign patients to either the intervention or control in ratio 1:1. While croup is common between 6 months and 5 years, a typical croup affects children between 6 months and 3 years. Based on this, we will randomize such that this age category (6 months-3years) has almost similar distribution in each arm., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: 0.15 mg/kg dexamethasone, outcomesModule primaryOutcomes measure: Return visits or readmissions to the hospital, secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272357, orgStudyIdInfo id: Antiarrhythmic drugs, briefTitle: The Use of Antiarrhythmic Drugs in Pediatrics, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: A study on the use of antiarrhythmic drugs in pediatric age group, in Assiut University Children's Hospital, a clinical audit, conditionsModule conditions: Antiarrhythmic Drug Adverse Reaction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 158, type: ESTIMATED, armsInterventionsModule interventions name: Antiarrhythmic drugs, outcomesModule primaryOutcomes measure: Detect the rate of use of antiarrhythmic drugs in pediatrics and the different indications for them other than the control of arrhythmia., eligibilityModule sex: ALL, minimumAge: 30 Days, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272344, orgStudyIdInfo id: CHUBX 2022/38, briefTitle: Remote Programming of Cardiac Implantable Electronic Devices 2, acronym: REACT 2, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-24, primaryCompletionDateStruct date: 2024-10-24, completionDateStruct date: 2024-10-24, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University Hospital, Bordeaux, class: OTHER, descriptionModule briefSummary: Cardiac Implantable Electronic Devices (CIEDs) such as pacemakers and implantable cardioverter defibrillators need to be regularly and systematically interrogated and reprogrammed to ensure proper functioning. While remote monitoring allows for partial interrogation at a remote location, full CIED check-up and reprogramming is only possible when the patient visits a cardiologist capable of performing device programming. This can be challenging for patients and may cause unnecessary delays, particularly in settings of limited resources, enforced physical distancing, and quarantines. In this study we aim to evaluate our previously validated remote programming solution (REACT study, NCT05366660) in outpatient device clinics which are close to the patient's home but remote from the CIED expert., conditionsModule conditions: Pacemaker, conditions: Defibrillator, conditions: Telemedecine, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, single-center, single-arm, pairwise comparison trial, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Teleconsultation, outcomesModule primaryOutcomes measure: assess the satisfaction of patients benefiting from a teleconsultation compared to a standard consultation at hospital, secondaryOutcomes measure: Time saving for patient, secondaryOutcomes measure: Savings on medical transport, secondaryOutcomes measure: Costs associated with teleconsultation, secondaryOutcomes measure: safety of teleconsultation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bordeaux University Hospital, status: RECRUITING, city: Pessac, zip: 33604, country: France, contacts name: Sylvain MD Ploux, role: CONTACT, phone: (0)5 57 65 64 71, phoneExt: +33, email: sylvain.ploux@chu-bordeaux.fr, contacts name: Estel HUGOT, role: CONTACT, phone: (0)5 57 62 32 26, phoneExt: +33, email: estel.hugot@chu-bordeaux.fr, contacts name: Sylvain MD Ploux, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.81011, lon: -0.64129, hasResults: False
protocolSection identificationModule nctId: NCT06272331, orgStudyIdInfo id: NL83162.091.22, briefTitle: Milk and Plant Protein Digestion, acronym: MAPP-D, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Wageningen University, class: OTHER, collaborators name: FrieslandCampina, descriptionModule briefSummary: The goal of this study is to explore the effect of protein quantity and quality in plant-based drinks. Healthy normal-weight males aged between 18 and 45 years will be included in the study.The main objectives are to examine the differences in postprandial amino acid profiles, and to examine differences in gastric behavior between cow's milk and plant based drinks.Participants will visit after an overnight fast three times and have blood draws before and after consumption one of the study drinks. There will be MRI scans of the stomach before and after consumption of the drink to assess gastric behavior., conditionsModule conditions: Food Digestion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Low-protein plant-based drink, interventions name: High-protein plant-based drink, interventions name: Cow's milk, outcomesModule primaryOutcomes measure: Postprandial plasma amino acid profile as characterized by the peak height and iAUC, secondaryOutcomes measure: Gastric behavior, secondaryOutcomes measure: Postprandial plasma response, otherOutcomes measure: Verbal ratings of wellbeing, otherOutcomes measure: MRI markers of digestion, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Human Research Unit - Division of Human Nutrition and Health, status: RECRUITING, city: Wageningen, zip: 6708WE, country: Netherlands, contacts name: Paul Smeets, PhD, role: CONTACT, phone: + 31317484681, email: paul.smeets@wur.nl, contacts name: Paul Smeets, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.97, lon: 5.66667, hasResults: False
protocolSection identificationModule nctId: NCT06272318, orgStudyIdInfo id: 74131, briefTitle: Vital Signs Blood Pressure Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: The purpose of this study is collect subject vitals with a blood pressure cuff, electrocardiogram (ECG), and photoplethysmogram (PPG). This data can then be used to develop a reliable, accurate, noninvasive, and continuous blood pressure monitoring device., conditionsModule conditions: Cardiovascular Diseases, conditions: Hypertension, conditions: Blood Pressure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Blood Pressure Cuff, EKG, PPG, outcomesModule primaryOutcomes measure: Collection of Subject Name (optional), primaryOutcomes measure: Collection of Subject Height, primaryOutcomes measure: Collection of Subject Weight, primaryOutcomes measure: Collection of Subject Age, primaryOutcomes measure: Collection of Subject Medical Comorbidities, primaryOutcomes measure: Blood Pressure Measurement, primaryOutcomes measure: Collection of ECG Waveforms, primaryOutcomes measure: Collection of PPG Waveforms, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272305, orgStudyIdInfo id: 49RC21_0301, briefTitle: TREC - Evaluation of the Impact of Eversion Technical Features on the Rate of Carotid Restenosis, acronym: TREC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University Hospital, Angers, class: OTHER_GOV, descriptionModule briefSummary: Restenosis due to myo-intimal hyperplasia remains a concern after carotid endarterectomy. It occurs in around 6% of cases. Several risk factors for restenosis have already been identified, such as smoking, hypertension, female gender, diabetes, dyslipidemia and small carotid diameter. The main objective of this prospective multicenter study was to determine whether the technical characteristics of the eversion technique have an influence on the rate of restenosis at 1 year.Between September 2021 and November 2022, we followed all patients undergoing carotid endarterectomy by eversion in 8 French hospitals. Demographic data, operative indications and technical characteristics of the endarterectomies performed were collected. These were defined by the circumferential nature of the carotid bulb according to 3 types (TREC A, B or C), and the length and depth of the endarterectomy according to anatomopathological reports. Post-operative complications were collected as much as doppler ultrasonography at three months and 1 year to quantify restenosis., conditionsModule conditions: Hyperplasia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: This research does not require any specific investigation and does not imply any modification of treatment., outcomesModule primaryOutcomes measure: Rate of restenosis, secondaryOutcomes measure: Morbidity and mortality rate, secondaryOutcomes measure: Major cardiological event, secondaryOutcomes measure: Minor neurological events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False